Discover
MPLT
MapLight Therapeutics, Inc.
36.08
2 x 26.18
2 x 44.48
bid
ask
+
0.24
0.67%
2 @ 06:21 AM
36.50 +0.42 (1.16%)
| Ytd | 105.35% | |
| 1y | 96.73% |
33.92
day range
36.84
12.24
52 week range
37.02
| Open | 35.48 | Prev Close | 35.84 | Low | 33.92 | High | 36.84 | Mkt Cap | 1.64B |
| Vol | 420.42K | Avg Vol | 358.77K | EPS | -4.41 | P/E | N/A | Forward P/E | -8.30 |
| Beta | N/A | Short Ratio | 6.55 | Inst. Own | 55.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 29.66 | 200-d Avg | 21.65 | 1yr Est | 39.55 |
MPLT News
benzinga.com
Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Ta
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with
benzinga.com
Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowe
benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
benzinga.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements
benzinga.com
MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Sp
The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses plann
benzinga.com
Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36
Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises t